Colibri Heart Valve has received an issue notification from the US Patent and Trademark Office regarding the forthcoming granting of a US Patent titled, “Percutaneous replacement heart valve and a delivery and implantation system.” This will be Colibri’s twelfth patent and will issue on 8 September, 2015.
The patent is a utility patent directed to an assembly that includes a transcatheter heart valve with a tubular structure away from its central portion that flares at both ends. The assembly further includes a pusher member and a delivery sheath. The associated patent application has priority claims with content dating back to 4 January, 2002. It is expected that the patent will provide Colibri with broad protection for the claimed assembly until 4 January, 2022. This patent issuance represents the fifth Colibri THV patent allowed/granted in 2015.
“Colibri has invested heavily in maximising its intellectual property footprint, which has been significantly bolstered with the addition of this patent,” stated Joseph B Horn, Colibri’s president and chief executive officer. “This soon-to-issue patent covers a percutaneous replacement heart valve and a delivery and implantation system with a priority date of 2002 that is both early and meaningful in the transcatheter heart valve market.”
A company press release notes that “with the strengthened patent portfolio, Colibri is positioned to accelerate development of a self-expanding heart valve programme to complement its clinical-stage disruptive balloon expandable heart valve technology.” The addition of a self-expanding programme positions Colibri to be the only company with both intellectual property and technology to develop pre-packaged, ready-for-use, balloon and self-expanding transcatheter heart valve technology for aortic, mitral, and pulmonary applications.
